# Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

> **NCT02935790** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 1 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** ACY-241
- **DRUG:** nivolumab
- **DRUG:** ipilimumab

## Key facts

- **NCT ID:** NCT02935790
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-30
- **Primary completion:** 2017-04-07
- **Final completion:** 2017-04-07
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2017-08-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02935790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02935790, "Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02935790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*